Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isa-VRD vs VRD in High-Risk, Transplant-Ineligible Newly Diagnosed Multiple Myeloma
NCT07334535Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2026
- Primary completion
- Jul 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of isatuximab in multiple myeloma (MM), sponsored by Peking Union Medical College Hospital. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07334535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07334535.